In two recent clinical trials of patients with chronic kidney disease (CKD) with or without diabetes (DAPA-CKD and EMPA-KIDNEY trials), the SGLT2 inhibitors dapagliflozin and empagliflozin significantly decreased the combined risk of a sustained decline in the estimated glomerular filtration rate, end-stage renal disease, and death from renal or cardiovascular causes (10, 11). This evidence concerns the gene SLC5A2 and diabetes mellitus.